Newsfeeds - Spark Newswire

1 minute read

Earnings

Preview: AIM ImmunoTech’s Earnings

Today, 11:04 AM

AIM ImmunoTech (AMEX:AIM) is set to give its latest quarterly earnings report on Friday, 2022-05-06. Here's what investors need to know before the announcement. Analysts estimate that AIM ImmunoTech will report an earnings per share (EPS) of $-0.07.

AIM

2 minute read

20 Stocks Moving in Tuesday’s Pre-Market Session

By Lisa Levin

Today, 11:04 AM

Gainers Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares rose 38% to $3.69 in pre-market trading. Sonoma Pharmaceuticals and MicroSafe Group DMCC reported EPA approval for Nanocyn hospital-grade disinfectant in the U.S.

AIM

3 minute read

26 Stocks Moving in Monday’s Pre-Market Session

By Lisa Levin

Today, 11:04 AM

Gainers ERYTECH Pharma S.A. (NASDAQ: ERYP) shares rose 88.4% to $2.30 in pre-market trading. Erytech Pharma recently announced publication of results from Eryapasse Phase 2 trial as treatment for hypersensitive ALL in the British Journal of Haematology.

ACON

3 minute read

26 Stocks Moving in Thursday’s Pre-Market Session

By Lisa Levin

Today, 11:04 AM

Gainers Redbox Entertainment Inc. (NASDAQ: RDBX) rose 31.9% to $3.35 in pre-market trading after jumping around 25% on Wednesday.

4 minute read

54 Biggest Movers From Yesterday

By Lisa Levin

Today, 11:04 AM

Gainers

ACC

1 minute read

AIM ImmunoTech Provides Progress An Advancement Of Ampligen Clinical Development Program For The Treatment Of Pancreatic Cancer

By Benzinga Newsdesk

Today, 11:04 AM

- Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with advanced pancreatic cancer - Company engages world-renowned CRO,

AIM

1 minute read

AIM ImmunoTech Shares Jump On Positive Data From Ampligen Study In Breast Cancer Setting

By Vandana Singh

Today, 11:04 AM

AIM ImmunoTech Inc (NYSE: AIM) has

AIM

3 minute read

AIM ImmunoTech Highlights Abstract Accepted For Poster Presentation By Roswell Park Comprehensive Cancer Center At American Association For Cancer Research Meeting Apr. 12 At 2:30 p.m. EDT

By Benzinga Newsdesk

Today, 11:04 AM

AIM ImmunoTech Inc. (NYSE:AMERICAN) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders,

AIM

1 minute read

FDA Removes Clinical Hold On AIM ImmunoTech’s Mid-Stage Ampligen Trial In Pancreatic Cancer

By Vandana Singh

Today, 11:04 AM

The FDA has lifted the clinical hold on AIM ImmunoTech Inc’s (NYSE:AIM) investigational new drug (IND) application for a Phase 2 study…

AIM

3 minute read

AIM ImmunoTech Appoints Robert Dickey, IV As CFO

By Benzinga Newsdesk

Today, 11:04 AM

AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune

AIM